Lucid Diagnostics reports Q3 adjusted EPS (20c), consensus (22c)
The Fly

Lucid Diagnostics reports Q3 adjusted EPS (20c), consensus (22c)

Reports Q3 revenue $1.17M, consensus $1.14M. “The third quarter and recent weeks have been a transformational period for Lucid, including two key milestones announced last week,” said Lishan Aklog, M.D., Lucid’s Chairman and CEO. “We are now fully armed with a complete body of outstanding clinical data to go along with a renewed commercial focus on programs designed to drive near-term revenue. Our team is ready to make our final push towards broad reimbursement, including our upcoming submission formally seeking Medicare coverage of EsoGuard. We are energized by the vast clinical and market opportunity before us as we seek to expand patient access to our groundbreaking technologies to detect esophageal precancer, and drive shareholder value.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App